Uppsala, Sweden – February 19, 2020 – Orexo AB (publ.), today invites investors, analysts and media to attend the company´s Capital Markets Day, taking place in Stockholm, Sweden, on
March 17, at Helio GT30, Grev Turegatan 30.

Members of Orexo’s management team, including recently appointed EVP Digital Therapeutics, Dennis Urbaniak, will provide an update on the company´s strategy, R&D pipeline and business opportunities within digital health. Also speaking will be Dr. Mario Weiss, CEO and Founder of GAIA AG, a global leader in digital therapeutics.

The agenda for the day is displayed below. To register for the event please use the following link


 Time pm CET Topic or activity Presenter
1:00 – 1.30 Registration and coffee
Part 1 – Growth Strategy
1:30 – 1:50 Strategy for short- and long-term growth Nikolaj Sørensen, CEO and President
1:50 – 2:10 Growing the Zubsolv® franchise Robert DeLuca, President of
Orexo US Inc.
Part 2 – Pharma R&D Pipeline
 2:10 – 2:30 A pipeline with significant future potential Johannes Doll, EVP and
Chief Commercial Officer
2:30 – 2:35 Q&A session
2:35 – 2:45 Break
Part 3 – Digital Therapeutics (DTx)
2:45 – 3:10 DTx – new frontiers in patient care Dennis Urbaniak,
EVP Digital Therapeutics
3:10 – 3:40 GAIA – a global leader in digital therapeutics Dr. Mario Weiss, CEO and founder of GAIA AG
 3:40 – 3:55 Q&A session
 3:55 – 4:00 Concluding remarks Nikolaj Sørensen, CEO and President
 4:00 Mingle and buffet

Robert Rönn, VP and Head of R&D, and Mike Sumner, Chief Medical Officer, will attend the
Q&A sessions.

Minor changes can be done in the agenda ahead of the event.

For further information, please contact:

Orexo AB (publ.)
Lena Wange, IR and Communications Manager
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com

About Orexo

Orexo develops and commercializes improved pharmaceuticals and digital therapeutics, addressing unmet medical needs mainly within the growing space of addiction. Approved products are commercialized by Orexo in the US or worldwide via partners. Orexo’s main market is the US for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv®, for the treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 844.8 million and the number of employees was 128. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

The information was submitted for publication at 8:00 am CET, on February 19, 2020.